Clinical and Experimental Vaccine Research

  • 제12권2호
  • /
  • Pages.116-120
  • /
  • 2023
  • /
  • 2287-3651(pISSN)
  • /
  • 2287-366X(eISSN)
대한백신학회 (The Korean Vaccine Society)
권호 표지
DOI QR코드

DOI QR Code

Changes in SARS-CoV-2 antibody titers 6 months after the booster dose of BNT162b2 COVID-19 vaccine among health care workers

  • Takeshi Mochizuki (Department of Rheumatology and Orthopedic Surgery, Kamagaya General Hospital) ;
  • Takaki Hori (Department of Cardiovascular Surgery, Kamagaya General Hospital) ;
  • Koichiro Yano (Department of Orthopedic Surgery, Tokyo Women's Medical University) ;
  • Katsunori Ikari (Department of Orthopedic Surgery, Tokyo Women's Medical University) ;
  • Ken Okazaki (Department of Orthopedic Surgery, Tokyo Women's Medical University)
  • 투고 : 2022.09.24
  • 심사 : 2023.03.31
  • 발행 : 2023.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: In Japan, the data on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers after the booster dose of the coronavirus disease 2019 (COVID-19) vaccine are insufficient. The aim of this study is to evaluate changes in SARS-CoV-2 antibody titers before, 1, 3, and 6 months after the booster dose of the BNT162b2 COVID-19 vaccine among health care workers. Materials and Methods: A total of 268 participants who received the booster dose of the BNT162b2 vaccine were analyzed. SARS-CoV-2 antibody titers were measured before (baseline) and at 1, 3, and 6 months after the booster dose. Factors associated with changes in SARS-CoV-2 antibody titers at 1, 3, and 6 months were analyzed. Cutoff values at baseline were calculated to prevent infection of the omicron variant of COVID-19. Results: The SARS-CoV-2 antibody titers at baseline, and 1, 3, and 6 months were 1,018.3 AU/mL, 21,396.5 AU/mL, 13,704.6 AU/mL, and 8,155.6 AU/mL, respectively. Factors associated with changes in SARS-CoV-2 antibody titers at 1 month were age and SARS-CoV-2 antibody titers at baseline, whereas changes in SARS-CoV-2 antibody titers at 3 and 6 months were associated with the SARS-CoV-2 antibody titers at 1 month. The cutoff values of the SARS-CoV-2 antibody titers at baseline were 515.4 AU/mL and 13,602.7 AU/mL at baseline and 1 month after the booster dose, respectively. Conclusion: This study showed that SARS-CoV-2 antibody titers increase rapidly at 1 month after the booster dose of the BNT162b2 vaccine and begin to decrease from 1 to 6 months. Hence, another booster may be needed as soon as possible to prevent infection.

키워드

참고문헌

  1. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar. N Engl J Med 2022;386:1804-16.
  2. Tartof SY, Slezak JM, Puzniak L, et al. Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study. Lancet Reg Health Am 2022;9:100198.
  3. Moreira ED Jr, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine. N Engl J Med 2022;386:1910-21.
  4. Mielke N, Johnson S, Bahl A. Boosters reduce in-hospital mortality in patients with COVID-19: an observational cohort analysis. Lancet Reg Health Am 2022;8:100227.
  5. Mattiuzzi C, Lippi G. Efficacy of COVID-19 vaccine booster doses in older people. Eur Geriatr Med 2022;13:275-8.
  6. Favresse J, Bayart JL, Mullier F, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect 2021;10:1495-8.
  7. Padoan A, Cosma C, Bonfante F, et al. Neutralizing antibody titers six months after Comirnaty vaccination: kinetics and comparison with SARS-CoV-2 immunoassays. Clin Chem Lab Med 2021;60:456-63.
  8. Mochizuki T, Hori T, Yano K, Ikari K, Okazaki K. Factors associated with change in SARS-CoV-2 antibody titers from three to six months after the administration of the BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Japan: a prospective study. Intern Med 2022;61:1139-43.
  9. Yu J, Collier AY, Rowe M, et al. Neutralization of the SARSCoV-2 Omicron BA.1 and BA.2 variants. N Engl J Med 2022;386:1579-80.
  10. Bergwerk M, Gonen T, Lustig Y, et al. COVID-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385:1474-84.
  11. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032-40.
  12. Um J, Choi YY, Kim G, et al. Booster BNT162b2 COVID-19 vaccination increases neutralizing antibody titers against the SARS-CoV-2 Omicron variant in both young and elderly adults. J Korean Med Sci 2022;37:e70.
  13. Loubet P, Laureillard D, Martin A, Larcher R, Sotto A. Why promoting a COVID-19 vaccine booster dose? Anaesth Crit Care Pain Med 2021;40:100967.
  14. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med 2021;385:1393-400.